ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 26.56

+2.6%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	12/30/2004 5:51:58 PM
	Read Replies (1) of 588

Brian Lundstrom has served as our Senior Vice President, Business Development since November 2004. Prior to joining us, Mr. Lundstrom held the position of Vice President, Business Development at Genzyme Corporation where he led the integration and outlicensing of assets from SangStat Medical Corporation that he had joined in 2000 and helped grow through partnering until sale of the company to Genzyme in 2003. Earlier in his career, Mr. Lundstrom held increasingly senior business, clinical and product development positions with discovery-based and commercially operating Oxford GlycoSciences (1998-2000), Novo Nordisk (1990-1997) and Immuntech (1986-1989). Mr. Lundstrom has negotiated over 40 deals on discovery technologies, clinical-stage product candidates and marketed products. He holds an M.S. in biotechnology from the Danish Technical University and an MBA equivalent degree in international business and finance from Copenhagen Business School and Seattle University. (website updated)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next